Against 198 viridans group streptococci, 25 Streptococcus bovis strains, and 5 Cardiobacterium hominis strains, MICs of DX-619, a des-F(6)-quinolone, were between 0.004 and 0.25 g/ml. These MICs were lower than those of other quinolones (<0.008 to >32 g/ml). ␤-Lactam MICs were between <0.008 and 16 g/ml. Azithromycin resistance was found in most species, while most were telithromycin susceptible. Glycopeptides and linezolid were active against viridans group strains but inactive against C. hominis.
Organisms in the viridans streptococcal group are normal inhabitants of the human respiratory tract above the larynx. The classification of these organisms has been a matter of dispute and is still in a state of flux, with disagreements in the precise nomenclature and the need for laborious and timeconsuming methods for accurate and reproducible species identification (14, 16) . Such methods are beyond the capability of the routine clinical microbiology laboratory, so these strains usually remain unidentified to the species level.
With proper classification, it has become clear that disease caused by viridans group streptococci is, to a large extent, species specific. Streptococcus mutans strains are involved in the pathogenesis of dental caries, and those in the group comprising S. mitis, S. salivarius, and S. sanguinis are the main causative organisms in subacute bacterial endocarditis (7) . By contrast, organisms grouped together by the United Kingdom classification as S. milleri (S. anginosus, S. constellatus, S. intermedius; beta-hemolytic group F streptococci) are involved (alone or in combination with other aerobic, microaerophilic, and anaerobic species) in the pathogenesis of deep pyogenic processes, such as liver and brain abscesses (13) . Cardiobacterium hominis, a gram-negative rod, is another cause of subacute endocarditis and was included because of the lack of susceptibility data for this species (6, 11) . Although S. bovis is not classified as a viridans group streptococcus, it was included in this study because of the paucity of data related to quinolone resistance in this species.
It is possible that the pneumococcus originally obtained its resistance transposon(s) from the viridans group more than 30 years ago; Janoir et al. (8) have reported in vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans group streptococci in vitro. Additionally, resistance to ␤-lactams and other agents is increasingly seen for viridans group streptococci, necessitating a search for other therapeutic modalities (4, 13, 15) . DX-619 is a new des-F(6)-quinolone with excellent activity against grampositive organisms (1, 5, 17) . In this study we tested the activity of DX-619 and compared it to the activities of sitafloxacin, levofloxacin, moxifloxacin, gatifloxacin, penicillin G, amoxicillin/clavulanate, azithromycin, telithromycin, vancomycin, teicoplanin, and linezolid against a spectrum of viridans group streptococci, S. bovis strains, and C. hominis strains.
Viridans group streptococci (Table 1) were all recent clinical isolates identified to the species level by standard CDC-recommended methodology (6, 14) . Apart from 14 strains isolated between 1997 and 1999, all others were isolated from sites in North America, Latin America, and Europe between 2001 and 2004. A total of 198 viridans group streptococci, 25 S. bovis strains, and 5 C. hominis strains were tested. Viridans group streptococci were cultured from blood, wound drainage, sputum, abscesses, pleural fluid, invasive pulmonary infections, sinuses, eye, bronchoalveolar lavage specimens, cerebrospinal fluid, tissue, and ear/nose/throat. All C. hominis strains were obtained from the American Type Culture Collection (Rockville, Md.). Strains were frozen at Ϫ70°C in double-strength skim milk (Difco Laboratories, Detroit, Mich.) before use. DX-619 and sitafloxacin powders were obtained from Daiichi Pharmaceutical Co., Ltd., penicillin G from Sigma, Inc., St. Louis, Mo., and the remaining compounds from their respective manufacturers.
Susceptibility testing was done to determine agar dilution MIC by use of Mueller-Hinton plates supplemented with 5% sheep blood (3). Inocula were 10 4 CFU/spot, and plates were incubated overnight at 35°C in ambient air. C. hominis strains, which require increased humidity for growth (11) , were incubated in sealed jars with moist paper towels at the bottom of the jar. Standard quality control strains recommended by CLSI (Staphylococcus aureus ATCC 29213 and S. pneumoniae ATCC 49619) were included in each run (3) .
Quinolone-resistant strains were tested for mutations in portions of the gyrA and parC genes by PCR and sequencing by use of the following primers: gA2 (5Ј-TYATYGAYTAYGCYAT GAGTG-3Ј) and gA1 (5Ј-GCRCYATCHCCRTCCATDGAA CC-3Ј) for gyrA amplification and pC1 (5Ј-GTCCCTKGAGG AYATYATGGGAG-3Ј) and pC2 (5Ј-ARRCGNGCYTCNGT ATAACGC-3Ј) for parC amplification (Y. Onodera, personal All resistant strains were tested for the presence of a quinolone efflux mechanism by comparing ciprofloxacin agar dilution MICs in the presence and absence of 10 g/ml of reserpine (a known efflux pump inhibitor). A decrease of MIC of at least fourfold was used to define the presence of an efflux mechanism, although an efflux mechanism was believed to be present when the MIC (in the presence of reserpine) was at least twofold less (1 doubling dilution) than the MIC in the absence of reserpine (tests were done in duplicate) (2) .
MICs (g/ml) for the two quality control strains were as follows. For S. aureus ATCC 29213, the MICs of DX-619 were 0.004 (once) and 0.008 (eight times); that of sitafloxacin was 0.03 (nine times); that of levofloxacin, 0.25 (nine times); that of moxifloxacin, 0.06 (nine times); those of gatifloxacin, 0.06 (twice) and 0.12 (seven times); those of penicillin G, 0.5 (three times), 1 (four times), and 2 (twice); those of amoxicillin/ clavulanate, 0.25 (twice) and 0.5 (seven times); those of azithromycin, 0.5 (once) and 1 (eight times); that of telithromycin, 0.12 (nine times); those of vancomycin, 0.5 (four times) and 1 (five times); that of teicoplanin, 1 (nine times); and those of linezolid, 2 (four times) and 4 (five times). For S. pneumoniae ATCC 49619, the MIC of DX-619 was 0.016 (nine times); that of sitafloxacin, 0.06 (nine times); those of levofloxacin were 1 (seven times) and 2 (twice); those of moxifloxacin, 0.12 (three times) and 0.25 (six times); those of gatifloxacin, 0.25 (three times) and 0.5 (six times); those of penicillin G, 0.25 (once) and 0.5 (eight times); those of amoxicillin/clavulanate, 0.06 (eight times) and 0.12 (once); those of azithromycin, 0.12 (six times) and 0.25 (three times); that of telithromycin, 0.03 (nine times); those of vancomycin, 0.25 (eight times) and 0.5 (once); that of teicoplanin, 0.12 (nine times); and those of linezolid, 1 (four times) and 2 (five times).
Results of MIC testing are presented in Table 1 . As can be seen, DX-619 MICs for all strains ranged between 0.004 and 0.25 g/ml, with an overall MIC 50 of 0.016 g/ml and MIC 90 of 0.03 g/ml. By comparison, MICs of other quinolones ranged between Յ0.008 and Ͼ32 g/ml. However, when results for S. bovis were excluded, quinolone MICs ranged between Յ0.008 and 16 g/ml. By comparison, ␤-lactam MICs ranged between Յ0.008 and 16 g/ml, with higher MICs encountered for some S. mitis, S. sanguinis, S. mutans, and S. oralis strains. Azithromycin resistance was found in all species with the exception of S. constellatus, and C. hominis and all strains except for S. bovis were telithromycin susceptible, with MICs of Յ1 g/ml. All organisms except for the 5 C. hominis strains were inhibited by vancomycin and teicoplanin at Յ1 g/ml, while all strains but C. hominis and 10 viridans group strains were inhibited by linezolid at Յ2 g/ml (3). Quinolone resistance (defined as a levofloxacin MIC of Ն4 g/ml) (3) was found only in two strains of S. oralis, one strain of S. salivarius, and seven S. bovis species, and results of analysis of resistance mechanisms can be seen in Table 2 .
As described before, resistance was mostly caused by alterations in GyrA (Ser substitution at position 81) and/or ParC (Ser substitution at position 79 and Asp substitution at position 83) protein (9, 10, 18) . Double substitutions in ParC and GyrA resulted in high-level resistance isolates no. 116, 124, 132, and 216, and substitution in ParC or GyrA resulted in low-level resistance for isolates no. 68, 121, 122, and 193 (9, 10, 18) . To our knowledge, mutations H43D, G79C, and Y107I in GyrA and Y15D and M116I in ParC have not yet been described.
Low-level resistance in isolate no. 118 probably resulted from the presence of an efflux mechanism. Reserpine lowered the ciprofloxacin MICs in three other isolates with mutations in GyrA and ParC: no. 68, 193, and 216. Resistant isolate no. 125 had one previously undescribed mutation in ParC (Y15D); a decrease in the MIC in the presence of reserpine was not observed. This may suggest the presence of mutations in other quinolone resistance-determining regions (QRDR) or a different resistance mechanism which is not yet known in this strain. Although the presence of resistance mechanisms caused resistance to all other quinolones tested, DX-619 MICs were significantly lower (0.016 to 0.25 g/ml). Importantly, DX-619 MICs against quinolone-resistant strains with efflux and/or defined mutations in QRDR were a few dilutions higher than those seen in quinolone-susceptible strains but in no case exceeded 0.25 g/ml. By comparison, ␤-lactam and azithromycin resistance occurred frequently. All strains except 2 of S. bovis were susceptible to telithromycin, and all except the 5 C. hominis strains were susceptible to glycopeptides and had linezolid MICs of Յ2 g/ml, except for 10 viridans group strains which were linezolid resistant (3).
In summary, the excellent activity of DX-619 against the organisms tested in this study reflects findings by us as well as other authors of studies of DX-619 activity against quinolonesusceptible and -resistant pneumococci as well as other organisms (1, 5, 12, 17) . DX-619 was also active against strains that had known mechanisms for the development of quinolone resistance. Pharmacokinetic and pharmacodynamic as well as toxicity studies will be necessary to confirm the clinical applicability of the excellent activity of DX-619 against the organisms tested.
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